December 8, 2025Blood

Comparative analysis of severe infection risk and survival outcomes in DLBCL patients treated with CAR T-cell therapy versus standard chemoimmunotherapy: Insights from real-world data

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective cohort study reveals CAR T-cell therapy indicates lower severe infection incidence in DLBCL patients than standard chemoimmunotherapy.

To compare severe infection incidence and survival outcomes in DLBCL patients treated with CAR T-cell therapy versus standard chemoimmunotherapy.
Conducted a retrospective cohort study utilizing TriNetX electronic health records.
Stratified adult DLBCL patients into CAR T-cell and standard chemoimmunotherapy cohorts.
Exclusions included patients with prior malignancies or stem-cell transplants.
Evaluated outcomes over a 12-month follow-up period using propensity score matching.
1-year cumulative incidence of severe infection was 10.5% in CAR T patients vs 13% in R-CHOP/R-EPOCH patients.
Risk ratio of developing sepsis was 0.807 (p = 0.042), indicating a lower risk in CAR T patients.
Survival probability for patients with sepsis was similar between groups at 87% vs 86.7% at 12 months.

Chris A. Learn (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort study reveals CAR T-cell therapy indicates lower severe infection incidence in DLBCL patients than standard chemoimmunotherapy.